Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Feb 14, 2020 6:16pm
164 Views
Post# 30694038

RE:RE:RE:All be careful

RE:RE:RE:All be careful Yup the risk of the unknown. But the science is sound on ATE. Just nature of the beast with the delays.

ACST had sodium bicarb as the placebo. And it was superior to the medication.Problem was that anomoly was found in a cluster of the clinical trial sites....this why ate is taking very stringent measures to prevent events like that....but the trade off is potential delays.....hence why im betting on another delay after following up with a at least 50% of the clinics.

Make sure your DD is done.

fogduckker wrote: I sort of hate to say this but this is an example of why DD is so important, and even then you may get your head handed to you on a platter. There is absolutely no comparision between the scientist at ATE and PLI. I looked at that one and took a pass. For me personally,  I never committ hard to these pre-revenue sort of companies until I see something more or the thesis seems to be proving correct. And another thing, listening careful is VERY important. I would absolutely bet that Robert McW did not say it was a great buy! He might of said it had a promising future if it work. I am sure he qualified it as highly speculative. The pharma space is tough...very tough - have to admit in ACST for a lot and ouch!
I agree that there are a lot of shady guys out there. The pot sector was ripe with them. 
Good luck to all.


Bullboard Posts